Anavex Life Sciences Corp (AVXL)

[Anshu2]

With that knowledge/background, I'm surprised that you continue to insist that the confirmatory trial would be "precision medicine (PM)" trial --- i.e., it will show clinical benefit on only a selected subgroup (based on some biomarker) of patients. That can't be true.

If AVXL gets A A ---- presumably not based on any subgroup analysis within P2b/P3 --- then, the confirmatory trial will have to have almost the same inclusion/exclusion criteria as the P2b/P3. Else, it won't be confirming the basis of AA approval.